MASH: Epidemiology, Natural History, and Outcomes
Nov
2026
Description
This session presents population-level data on MASLD prevalence, fibrosis progression, and outcomes, including AI-based analyses of NHANES data and community screening cohorts.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 1A
Contemporary Trends in healthcare and economic burden of MASLD, MASH Cirrhosis, and ACLF among Hospitalized Patients in the United States: A nationwide analysis (2016-2023)
Aalam Sohal | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 1A
Is MASLD part of cardiovascular-kidney-metabolic syndrome? Genetic evidence for a causal, metabolically-mediated CKM-to-ALT effect.
Eleonora Scorletti, MD, PhD | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - Bluebird Ballroom 1A
Steatosis is Common, Fibrosis is Selective: Prevalence and Metabolic Phenotyping of MASLD in a Prospective Community Screening Cohort
Alina M. Allen, MD | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - Bluebird Ballroom 1A
Advanced Fibrosis in MASLD Shows Early Male Predominance but No Postmenopausal Female Surge
Callie J Zaborenko, PhD | Abstract Presenter
